# US 8,278,093 B2 · Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,093 B2
- Document ID: US8278093B2
- Status: Granted
- Kind: B2
- Application number: 13/013,752
- Filed: 2011-01-25
- Published: 2011-07-21
- Granted: 2012-10-02
- Earliest claimed: 2002-12-23
- Assignees: Vical Incorporated
- Inventors: Gary G. Hermanson; Andrew J. Geall; Mary Kopke Wloch
- Web page: https://patentgrep.com/patent/US8278093B2

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 39/12: Viral antigens
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07K 14/005: from viruses
- C07K 14/045: Cytomegalovirus
- A61K 35/763: Herpes virus
- A61K 38/162: {from virus}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

## Claims

### Claim 1

A composition comprising:
(a) an isolated polynucleotide comprising SEQ ID NO:13;
(b) an isolated polynucleotide comprising SEQ ID NO:5; and
(c) an adjuvant or transfection facilitating agent comprising CRL1005 and BAK.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the CRL1005 and BAK are present at concentrations selected from the group consisting of:
0.3 mM BAK and 7.5 mg/ml CRL 1005,
0.3 mM BAK and 34 mg/ml CRL 1005, and
0.3 mM BAK and 50 mg/ml CRL 1005.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the polynucleotide of (a) is DNA operably associated with a promoter, and wherein the polynucleotide of (b) is DNA operably associated with a promoter.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the polynucleotide of (a) and the polynucleotide of (b) are situated on a single plasmid.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the polynucleotide of (a) and the polynucleotide of (b) are situated on separate plasmids.

### Claim 6 (depends on 1)

A method of eliciting or enhancing an immune response to CMV in a human or in a human tissue comprising administering the composition of claim 1 to the human or human tissue.

### Claim 7 (depends on 2)

A method of eliciting or enhancing an immune response to CMV in a human or in a human tissue comprising administering the composition of claim 2 to the human or human tissue.
